Rheumatology

Back to articles

Perioperative timing of infliximab did not alter the risk of serious infection

KEY POINT

The risk of serious infections within 30 days or 1 year after elective hip or knee surgery was similar in patients who stopped infliximab (Remicade—Janssen) within 2 to 4 weeks of surgery compared with those who stopped therapy for a longer duration (i.e., 8–12 wk before surgery), according to results of a retrospective study published in Arthritis Care and Research.